Please Wait.....
Report
United States Drug Delivery Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)
Market Report I 2025-06-01 I 75 Pages I Mordor Intelligence
United States Drug Delivery Devices Market Analysis
The United States drug delivery devices market is valued at USD 51.24 billion in 2025 and is forecast to reach USD 75.20 billion by 2030, expanding at a 6.71% CAGR. Growth is grounded in the nation's rising chronic-disease burden, continual product innovation, and a decisive pivot toward patient-centric therapy that favors self-administration and home care.[1]Traditional modalities remain relevant, yet device makers are layering connectivity, sensors, and analytics onto proven platforms to improve adherence and real-world outcomes. Hospitals continue to anchor demand, but reimbursement trends and high deductibles are funneling volume into ambulatory clinics and living rooms, reshaping channel economics. Competitive intensity is sharpening around biologics-ready injectors, smart inhalation systems, and on-body pumps that reduce clinic visits. At the same time, the FDA's Digital Health Advisory Committee is shortening feedback loops for software-driven devices while maintaining a stringent safety bar, creating both opportunity and compliance cost for innovators.
United States Drug Delivery Devices Market Trends and Insights
Rise in Self-Administration Preferences Driven by High Patient Deductibles and Telehealth Adoption
Demand for convenient dosing formats is accelerating as patients shoulder higher out-of-pocket costs. Telehealth visits rose sharply during the pandemic and remain elevated, enabling clinicians to coach users on connected pens, pumps, and inhalers without in-person training. Hospitals, facing USD 115 billion in 2023 drug spend, encourage take-home therapies to trim length-of-stay and pharmacy overhead. The FDA's April 2025 clearance of CT-132, a digital therapeutic for migraine, underscores momentum for software-enhanced regimens that transfer care into the home. Continuous glucose monitoring now starts earlier in diabetes journeys, aligning device selection with individual lifestyle and boosting confidence in self-managed dosing.
Expanding Biologics Pipeline Necessitating Advanced Parenteral Delivery Platforms
Large-molecule therapies represent a growing share of FDA approvals, demanding devices that maintain viscosity control, temperature stability, and precise micro-dosing[1]. Wearable injectors capable of 5-10 mL subcutaneous delivery are entering trials, offering at-home alternatives to infusion centers. Early device strategy is now embedded in molecule design as drug makers weigh formulation viscosity against patient comfort. Contract manufacturers with polymer expertise enjoy a widening moat, especially in Boston-area and Bay-area biotech clusters. Industry attention to biologics-ready systems expanded further after AstraZeneca highlighted lipid nanoparticle and oral biologic platforms in its pipeline update.
Stringent FDA Premarket Review for Combination Products Extending Time-to-Market
Approval cycles for novel drug-device combinations can stretch to 36 months, straining venture-backed developers. Draft user-fee legislation aims to streamline reviews but will introduce new documentation layers in the near term. Firms now integrate regulatory specialists early in concept design, adding cost and prolonging R&D. Larger incumbents with established quality systems widen competitive distance as smaller entrants wrestle with documentation rigor. Any leadership turnover or budget pressure at FDA may influence review cadence and resource allocation.
Other drivers and restraints analyzed in the detailed report include:
Technological Advancement and Product Innovation / High Burden of Chronic Disease / Reimbursement Uncertainty for Digital Companion Applications /
For complete list of drivers and restraints, kindly check the Table Of Contents.
Segment Analysis
Inhalers record the fastest 9.13% CAGR, outpacing the broader United States drug delivery devices market yet still trailing Syringes and Needles that hold 30.34% share. This surge stems from propellant redesigns and digital dose-counters that assure correct technique, critical for the 25 million Americans managing asthma. GSK's low-carbon Ventolin prototype positions sustainability as a new differentiator.
Momentum in inhalation technology is steering investment into soft-mist and dry-powder platforms capable of systemic delivery of biologics. Needle-free injectors now attract users with strong aversion to sharps, while auto-injectors and pens leverage spring-loaded mechanics for precise biologic dosing at home. Implantable pumps fill long-term therapy niches such as ophthalmology inserts reviewed by the FDA in February 2025. These diverse modalities enlarge the addressable base and reduce single-technology dependence within the United States drug delivery devices market.
Injectables retained 42.12% share of the United States drug delivery devices market size in 2024 due to compatibility with biologics. Yet topical systems grow at 7.88% thanks to permeation enhancers, microneedle patches, and polymer films that deliver peptides through skin layers. Regulatory nods for migraine nasal sprays and ocular refillable implants demonstrate expanding options beyond needles.
Oral dosage formats remain favored for small molecules, supported by innovations in bioavailability boosters. Pulmonary delivery methods broaden into systemic applications, and transdermal GLP-1 patches target the obesity epidemic. Together these shifts diversify modality risk and spread growth vectors across the United States drug delivery devices market.
The United States Drug Delivery Devices Market Report is Segmented by Device Type (Inhalers, Transdermal Patch, and More), Route of Administration (Injectable, Topical, and More), Technology (Sustained/Controlled Release System, Targeted/Site-Specific Delivery, and More), Application (Diabetes, Cancer and More), and End Users (Hospitals, Ascs, and More). The Market and Forecasts are Provided in Terms of Value (USD).
List of Companies Covered in this Report:
Beckton Dickinson / Solventum / Johnson&Johnson / Medtronic / West Pharmaceutical Services / Insulet / Baxter / Boston Scientific / Terumo / Gerresheimer / Ypsomed / Tandem Diabetes Care / Antares Pharma (a Halozyme company) / Pfizer / Roche / Bayer / Sanofi / GlaxoSmithKline / Eli Lilly and Company / Novo Nordisk / AstraZeneca / Teva Pharmaceutical Industries / AptarGroup, Inc. / The Cooper Companies /
Additional Benefits:
The market estimate (ME) sheet in Excel format /
3 months of analyst support /
1 Introduction
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Self-Administration Preferences Driven by High Patient Deductibles and Telehealth Adoption
4.2.2 Expanding Biologics Pipeline Necessitating Advanced Parenteral Delivery Platforms
4.2.3 Technological Advancement and Product Innovation
4.2.4 High Burden of Chronic Disease
4.2.5 Increased Use of Advanced and Connected Drug Delivery Devices
4.2.6 CMS Home-Infusion Therapy Benefit and Hospital-at-Home Programs Fueling Demand for Portable Infusion Pumps
4.3 Market Restraints
4.3.1 Stringent FDA Premarket Review for Combination Products Extending Time-to-Market
4.3.2 Reimbursement Uncertainty for Digital Companion Applications
4.3.3 Rising Needlestick Injury Litigation Elevating Liability Insurance Premiums
4.3.4 Persistent Shortages of Medical-Grade Silicone and Specialty Polymers Disrupting Device Manufacturing Schedules
4.4 Value / Supply-Chain Analysis
4.5 Regulatory and Technological Outlook
4.6 Porter's Five Forces Analysis
4.6.1 Bargaining Power of Suppliers
4.6.2 Bargaining Power of Buyers
4.6.3 Threat of New Entrants
4.6.4 Threat of Substitutes
4.6.5 Intensity of Competitive Rivalry
5 Market Size and Growth Forecasts (Value-USD)
5.1 By Device Type
5.1.1 Inhalers
5.1.2 Transdermal Patches
5.1.3 Infusion Pumps
5.1.4 Syringes & Needles
5.1.5 Injection Pens
5.1.6 Auto-Injectors
5.1.7 Needle-Free Injectors
5.1.8 Implantable Drug Delivery Devices
5.1.9 Others
5.2 By Route of Administration
5.2.1 Injectable
5.2.2 Topical
5.2.3 Oral
5.2.4 Pulmonary
5.2.5 Ocular
5.2.6 Nasal
5.2.7 Others
5.3 By Technology
5.3.1 Sustained / Controlled Release Systems
5.3.2 Targeted / Site-Specific Delivery
5.3.3 Biodegradable / Bioresorbable Systems
5.3.4 Smart & Connected Drug Delivery Devices
5.3.5 Needle-less Technologies
5.4 By Application
5.4.1 Diabetes
5.4.2 Cancer
5.4.3 Cardiovascular Diseases
5.4.4 Respiratory Diseases
5.4.5 Central Nervous System Disorders
5.4.6 Infectious Diseases
5.4.7 Others
5.5 By End User
5.5.1 Hospitals
5.5.2 Ambulatory Surgical Centers (ASCs)
5.5.3 Home Healthcare Settings
5.5.4 Clinics and Physician Offices
5.5.5 Others
6 Competitive Landscape
6.1 Market Concentration
6.2 Strategic Moves
6.3 Market Share Analysis
6.4 Company profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products and Services, and Recent Developments)
6.4.1 Becton, Dickinson and Company
6.4.2 Solventum
6.4.3 Johnson & Johnson
6.4.4 Medtronic plc
6.4.5 West Pharmaceutical Services, Inc.
6.4.6 Insulet Corporation
6.4.7 Baxter International Inc.
6.4.8 Boston Scientific Corporation
6.4.9 Terumo Corporation
6.4.10 Gerresheimer AG
6.4.11 Ypsomed AG
6.4.12 Tandem Diabetes Care, Inc.
6.4.13 Antares Pharma (a Halozyme company)
6.4.14 Pfizer Inc.
6.4.15 F. Hoffmann-La Roche Ltd.
6.4.16 Bayer AG
6.4.17 Sanofi
6.4.18 GlaxoSmithKline plc
6.4.19 Eli Lilly and Company
6.4.20 Novo Nordisk A/S
6.4.21 AstraZeneca plc
6.4.22 Teva Pharmaceutical Industries Ltd.
6.4.23 AptarGroup, Inc.
6.4.24 CooperSurgical, Inc.
7 Market Opportunities and Future Outlook
7.1 White-Space and Unmet-Need Assessment
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security